Ajax Therapeutics, Inc., a NYC-based biotechnology company applying computational chemistry and structure-based technologies to develop novel small molecules for hematologic malignancies, completed a $40m financing.
The round was led by EcoR1 Capital LLC with participation from additional new investor Boxer Capital, as well as co-founding investors Inning One Ventures and Schrödinger, Inc. (Nasdaq: SDGR). Existing research collaboration partners, Memorial Sloan Kettering Cancer Center (MSK) and NYU Langone Health, also participated in the financing. Concurrent with the financing, Scott Platshon, Partner of EcoR1 Capital, will join the Ajax Board of Directors.
The company intends to use the funds for the advancement of its lead drug development programs targeting hematologic malignancies and its drug discovery pipeline, including the potential expansion of research efforts beyond hematologic malignancies, in addition to building out the scientific and technical leadership team.
Ajax Therapeutics combines deep cancer and structural biology insights of its founding scientists with advanced computational drug discovery and protein structure platforms from founding partner, Schrödinger, Inc., to discover and develop more precisely designed therapies to address significant unmet needs for patients with hematologic malignancies.
FinSMEs
02/06/2021